Patient advocates in remission from MCL and FL discuss their experiences with treatment, as well as their views on CAR-T ...

U.S. pharmaceutical company Moderna announced on June 26 (local time) that it is entering the development of an “in vivo CAR-T” therapy. “In vivo CAR-T” is a technology that genetically modifies ...

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while ...

A new CAR T therapy targeting a newly identified tumor marker demonstrated preclinical activity and early clinical promise in ...

In addition to scalability, another opportunity is presented by clinical feasibility and performance. For example, lymphodepletion conditioning, which is a must for ex vivo-engineered CAR-T cells, is ...

Building on recent successes, scientists are focused on a promising new frontier: sending tiny particles into the body to ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

A new form of CAR T-cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while ...

AbClon announced on July 6 that its 'core technology related to CD30-targeting chimeric antigen receptor T-cell (CAR-T) ...

Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions Am J Manag Care. 2025;31(Spec. No. 13 ...

Once best known for treating blood cancers, CAR-T therapy is now being redesigned for solid tumors, autoimmune disease, and chronic viral infections, but the review shows that safety, persistence, and ...